NCT03970954 (FaCIL-2) is a Phase 1, PHASE2 clinical trial of low-dose IL-2 in Recurrent Miscarriage, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT03970954?

NCT03970954 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT03970954?

Interventions in NCT03970954: low-dose IL-2.

What condition does NCT03970954 study?

NCT03970954 studies Recurrent Miscarriage.

Is NCT03970954 still recruiting?

NCT03970954 is currently completed. Last updated 12 September 2025.

Last reviewed 2025-09-12 · How we verify

NCT03970954: FaCIL-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-dose Interleukin-2 in Women With Unexplained Miscarriages

Completed Phase 1, PHASE2 Last updated 12 September 2025

What this trial tests

Phase 1, PHASE2 trial testing low-dose IL-2 in Recurrent Miscarriage in 18 participants. Completed in 20 March 2024.

Timeline

5 January 2021

Primary endpoint
28 July 2023

20 March 2024

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	5 January 2021
Primary completion	28 July 2023
Estimated completion	20 March 2024
Sites	3 locations across France

Drugs / interventions tested

low-dose IL-2 — full drug profile →

Conditions studied

Recurrent Miscarriage — all drugs for Recurrent Miscarriage →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 18 to 40, female only, with Recurrent Miscarriage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to demonstrate the ability of low dose IL-2 to stimulate peripheral blood Tregs of women with unexplained repeated early spontaneous miscarriages for development of a therapy to prevent fetal rejection by low dose IL-2.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Low-dose interleukin-2 for recurrent early pregnancy loss: a proof-of-concept study
Klatzmann D, Mekinian A, ABISROR N, MCAVOY C, et al · · 2025 · DOI 10.21203/rs.3.rs-7093926/v1
Low-dose interleukin-2 for recurrent early pregnancy loss: a proof-of-concept study
Mekinian A, Abisror N, Mcavoy C, Ribet C, et al · · 2025 · DOI 10.1101/2025.06.13.25328550

Verify or expand the search:

Other recruiting trials for Recurrent Miscarriage

Currently open trials in the same condition.

NCT06826365 — Immune Cell Populations in the Endometrium · recruiting
NCT06356792 — Obstetrics , Prenatal Outcomes in Recurrent Miscarriage · recruiting
NCT06163092 — Chronic Endometritis and Benefits of Antibiotics in Women With Recurrent Miscarriage · recruiting
NCT05725512 — Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages · Phase 4 · recruiting
NCT03902912 — Effect of Prednisolone Treatment on Uterine Natural Killer Cells · Phase 3 · recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03970954 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 12 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03970954.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing